232275-50-2

Basic information

• Product Name: Methyl 2,6-dichloro-4-nitrobenzoate
• Synonyms: Methyl 2,6-dichloro-4-nitrobenzoate;3,5-Dichloro-4-(methoxycarbonyl)nitrobenzene
• CAS NO: 232275-50-2
• Molecular Formula: C₈H₅Cl₂NO₄
• Molecular Weight: 250.0356
• Mol File: 232275-50-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 2,6-dichloro-4-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2,6-dichloro-4-nitrobenzoate(232275-50-2)
• EPA Substance Registry System: Methyl 2,6-dichloro-4-nitrobenzoate(232275-50-2)

Safety Data

• Hazardous Substances Data: 232275-50-2(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 22509-50-8 2,6-dichloro-4-nitrobenzoic acid 
• 88135-16-4 2,6-dichloro-4-nitrobenzoyl chloride 
• 7149-69-1 1,3-dichloro-2-methyl-5-nitrobenzene 
• 74-88-4 methyl iodide 
• 99-99-0 1-methyl-4-nitrobenzene 

Downstream Products

• 232275-49-9 methyl 4-amino-2,6-dichlorobenzoate 
• 232275-56-8 methyl 2,6-dichloro-4-fluorobenzoate 
• 232275-53-5 methyl 4-bromo-2,6-dichlorobenzoate 
• 4641-38-7 2,6-Dichloro-4-hydroxybenzoic acid 
• 232275-51-3 4-bromo-2,6-dichloro-benzoic acid 
• 232275-55-7 2,6-dichloro-4-fluorobenzoic acid 
• 1613730-11-2 methyl 4-amino-2,6-dichloro-3-iodobenzoate 
• 1613730-12-3 methyl 4-amino-2,6-dichloro-3-((trimethylsilyl)ethynyl)benzoate 
• 1098619-73-8 2,6-dichloro-4-iodo-benzoic acid methyl ester 

Relevant articles and documents

A convenient synthesis of a lymphocyte function-associated antigen-1 (LFA-1) antagonist of 'Compound 4'

The lymphocyte function-associated antigen-1 (LFA-1) antagonist of 'Compound 4' was synthesised by a convenient route using cheap, commercially available starting materials and catalysts under mild reaction conditions and by easily handled reactions. The total yield in the preparation of 'Compound 4' was more than 38% via Sonogashira coupling of an iodide and an alkyne, reduction of the alkyne catalysed by Raney nickel and later steps involving hydrolysis of an ester, condensation of an acid and an amine and a final hydrolysis of an ester.

INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

The invention relates to indole carboxamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: Discovery of TR-14035, a dual α4β7/α4β1 integrin antagonist

α4β1 and α4β7 integrins are key regulators of physiologic and pathologic responses in inflammation and autoimmune disease. The effectiveness of anti-integrin antibodies to attenuate a number of inflammatory/immune conditions provides a strong rationale to target integrins for drug development. Important advances have been made in identifying potent and selective candidates, peptides and peptidomimetics, for further development. Herein, we report the discovery of a series of novel N-benzoyl-L-biphenylalanine derivatives that are potent inhibitors of α4 integrins. The potency of the initial lead compound (1: IC50 α4β7/α4β1 =5/33 μM) was optimized via sequential manipulation of substituents to generate low nM, orally bioavailable dual α4β1/α4β7 antagonists. The SAR also led to the identification of several subnanomolar antagonists (134, 142, and 143). Compound 81 (TR-14035; IC50 α4β7/α4β1 =7/87 nM) has completed Phase I studies in Europe. The synthesis, SAR and biological evaluation of these compounds are described.